Topic
hepatocellular carcinoma
News
6 Apr 2026
AstraZeneca’s Imfinzi‑based combo slows liver cancer progression in late‑stage trial
London‑based pharma major AstraZeneca has reported that its liver‑cancer therapy combination, built around its immunotherapy Imfinzi (durvalumab), significantly slowed disease progression…
Opinion
5 Mar 2026
Choose the Right Fat: A New Way to Cut Liver Cancer Risk in an Obese World
Obesity is reshaping the global cancer landscape, and the liver is one of its most vulnerable targets. Drawing on emerging…